AlphaMadera's AlphaVal page computes Janux Therapeutics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag JANX as undervalued, fairly valued, or overvalued.

What is Janux Therapeutics, Inc.'s fair value?

Fair value for JANX is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value JANX?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from JANX's most recent reported fundamentals.

JANX - Janux Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $28.57 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: JANX has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.